High-Resolution Biochemical Breast Imaging www.tcrt.org Positron emission mammography (PEM) provides images of biochemical activity in the breast with spatial resolution matching individual ducts (1.5 mm full-width at half-maximum).
Introduction
Back in the early days of digital subtraction angiography, incidental note was made of breast tumoral enhancement (1). This visibility relies on the physiology of increased blood flow seen with neovascularity, a property of invasive breast cancers. Since those early studies, other imaging modalities (MRI, CT, SestaMIBI scintimammography) have used blood flow to image breast cancers. To measure flow, MRI utilizes paramagnetic contrast agents (gadolinium), x-ray CT uses iodinated contrast agents, and single-photon scintimammography employs ionically charged chelates (2, 3). MRI and CT have the additional advantages of improved spatial resolution and tomographic methods. Initially enthusiastic reports of high sensitivity and specificity with flow-based methods have been replaced by more sober assessments due to two factors: (i) preinvasive breast cancers do not appear to have sufficiently increased blood flow to be reliably detected (i.e., limiting sensitivity) (4); and (ii) increased blood flow is not specific to cancer, but can often be seen in benign entities (i.e., limiting specificity). In the case of scintimammography, the spatial resolution properties of planar gamma cameras effectively limit visualization of small structures unless the lesions are within several centimeters of the camera face. When breast com-pression is applied to bring all lesions into the sweet spot of the gamma camera, this limitation is less formidable (5).
Recent surgical experience has shown that reduced sensitivity to the in situ form of breast cancer is very important, for several reasons: Preinvasive lesions represent a significant proportion of cancers (greater than 30% (6)). Data from sentinel node procedures show that ductal carcinoma in situ (DCIS) is much less likely to have spread to regional nodes than invasive cancer (7), thereby suggesting that detection of cancer at the preinvasive level provides the surgeon with the best opportunity to cure the patient by completely removing tumor cells. With respect to the task of planning surgical procedures, there has recently been a much greater awareness of the in situ component present in the vicinity of many invasive cancers. Outcome studies examining recurrence rates have shown that the presence of extensive intraductal component is a poor prognostic factor (8). When DCIS is seen at the surgical margin of a lumpectomy specimen, the likelihood of cancer recurrence is just as high as if there are invasive cancer regions at the margin.
A second factor limiting blood flow as a marker for characterizing and detecting cancers is low specificity. Initial reports suggested that blood flow kinetics could reliably predict whether a lesion was benign or malignant have not held up under large-scale investigations (9, 10). One strategy for dealing with low specificity has been to encourage biopsy of indeterminate lesions; however the expense and time associated with MRI-guided biopsies make this approach problematic.
Even with the problems associated with low overall accuracy, there is no question that MRI has brought a new awareness of the power of imaging in breast care. MRI provided surgeons with maps of multifocality and multicentricity for the first time, and appears very useful for detecting chest wall extension (2).
2-(F-18)-Fluorodeoxygluycose ("FDG") has been shown to accumulate in many neoplasms as well as in inflammatory states. FDG is an analog of glucose that is phosphorylated but does not proceed through the entire Krebs cycle leading to increased accumulation in glucose-avid cells (11). Examinations of breast cancer with FDG have included gamma camera imaging and whole-body PET scanners (12, 13) . Both of these instruments were shown to have limited utility in detecting early breast cancers because of spatial resolution issues (14). In 1993 (15-17) Thompson et al. introduced the concept of detecting FDG using dedicated breast PET scanners composed of detectors on both sides of a compressed breast. This configuration had the advantage of high-count efficiency (due to the relatively small volume of attenuating material between the detectors, and the proximity of the detectors to the radioactive sources). The theo-retical possibility of improved spatial resolution was not realized immediately, due to technical factors and lack of a bona fide reconstruction (16), but eventually a device was produced with spatial resolution that substantially improved upon whole-body PET (i.e., 1.5 mm full-width half-maximum as compared to 4 mm FWHM for whole-body PET scanners) and incorporated modern iterative limited-angle reconstruction techniques (18).
The application of gentle compression and/or immobilization during PET acquisition was termed positron emission mammography ("PEM"), and the resemblance of PEM scans to conventional x-ray mammographic views promised to aid in cross-modality correlation and biopsy guidance. A small fieldof-view PEM device was shown to have overall high accuracy of 89% in characterizing cancers (19). This system had a small field-of-view (50 mm by 50 mm) and as a result one cancer larger than the field-of-view was missed with the PEM system.
Materials and Methods
The current version of the PEM scanner is denoted "PEM Flex™", and has been tested clinically in two configurations ( Figure 1 ). The first configuration tested was mountable on stereotactic x-ray mammography cameras, and as a result had advantages in terms of x-ray correlation (20). Unfortunately, access to the posterior breast was limited by the stereotactic x-ray mammography camera, so that occasionally lesions in the posterior breast were not appreciated. A freestanding version of the PEM Flex device was constructed, resembling a small x-ray mammography system. This device configuration was able to get better coverage of the posterior breast. It is possible to convert the freestanding configuration into the mountable version by utilizing appropriate flanges as a transfer package. Clinical trials with this full-breast device (21) have shown high clinical accuracy (sensitivity 93%, specificity 83%, area under the ROC curve of 0.93), with high sensitivity preserved (91%) for intraductal cancers. Increased sensitivity did not come at a cost of reduced specificity, consistent with the earlier report (20).
The PEM Flex device consists of two detector heads, each of which contain approximately 2,000 lutetium-containing photo-detecting crystals, and whose design has been described elsewhere (22) . The detector heads are mounted in compression paddles that are applied to both sides of the breast under examination. The detector heads travel within the compression paddles so as to provide access for interventions (e.g., marking the breast for later ultrasound-guided biopsy). Stereotactic biopsy with PEM devices has been shown to have sub-millimeter accuracy using phantoms (23).
The user can select the travel distance in order to customize the examination to cover the area of interest. Custom elec-tronics packed in a compact-PCI crate produce lists of events that are then processed by an onboard computer. An iterative reconstruction provides images to the user while the images are being acquired. The graphical user interface (GUI) displays 12 slices to the user, with each slice having a z-depth corresponding to the compression distance divided by 12. Analysis tools allow measurement of region-of-interest parameters, distances, and (if digital x-rays were obtained) cross-correlative image fusion maps.
Results and Discussion
In practice, patients have been injected with 10-15 millicuries of FDG and imaged 1-3 hours after injection. Typical imaging protocols employ 10-minute medio-lateral oblique (MLO) views of both breasts. With a compression depth of less than eight centimeters, approximately one million coincident counts are reconstructed per breast. Assuming a typical volume for the entire breast of one liter, with 0.1 microcuries per cubic centimeter, we may estimate that 100 microcuries are in the breast of interest, with a very rough estimate of 2 × 10 9 disintegrations in all directions over a ten-minute period. The overall efficiency for collection of reconstructed gamma rays from the breast is thus roughly 0.05%. It is difficult to compare these efficiencies to whole-body PET, because the attenuation and slice width is different. As a broad comparison, however, typical count numbers for a one-hour acquisition of the torso and 7 millicurie injection using a modern whole-body PET scanner are in the 6 million count range, yielding an overall efficiency of 6 × 10 -6 , a hundred-fold decrease as compared to the PEM case (24).
Some users attempt to obtain cranio-caudal (CC) views of the medial breast (i.e., for 5 minutes). The axilla is often viewable in the mediolateral (MLO) view.
Interpretation of PEM scans is being examined in multi-center clinical trials. Interpretation guidelines include the presence of "hot spots", areas of mismatch between FDG-avid foci and the appearance of the same regions on x-ray mammography, and the presence of prominent ducts (suggestive of intraductal cancer) ( Figure 3) . Interpretive accuracy appears to be increased when the readers are experienced mammographers, with access to reference softcopy or original x-ray mammograms during interpretation of the PEM scans. The in-plane spatial resolution of the production version of the PEM Flex device is on the order of the size of ducts, explaining the high sensitivity of the device in detecting intraductal cancer deposits (21).
The use of FDG PEM in conjunction with digital spot mammography has already been implemented (19) . Recently, full-field digital x-ray mammography devices have been introduced, which would be natural platforms for combined x-ray/PEM investigational and clinical applications (25).
The current generation PEM Flex device has an intrinsic resolution equaling devices used for animal PET (See single slice images shown in Figure 4 ). Future PEM devices will no doubt include advanced materials and image processing techniques that will improve spatial resolution even further (26, 27). The quantitative measurement of biochemical changes in the breast provides exceptional opportunities for melding information technology with diagnostic imaging techniques. The clinical role for PEM will depend on results of ongoing and future clinical trials (21). For example, currently 10 milli-Curies are injected, which would prevent routine use in the general population as a screening method. Future detectors could be considerably longer (and therefore have significantly greater count sensitivity) if depth-of-interaction schemes were implemented (27). Depth-of-interaction schemes use photomultipliers or photodiodes on both sides of a long scintillator, unlike current readout schemes that only view light from one end of the scintillator crystal. With 3 cm long crystals, efficiency would be increased ten-fold, leading to a patient dose in the 100 mrem range, similar to conventional mammography.
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The greatest current strength of FDG PEM appears to be in the detection and delineation of in situ cancers, properties that are important in surgical planning (i.e., lumpectomy/ mastectomy). The current production version of the PEM Flex scanner includes apertures for marking landmarks on the patient's skin, or for inserting bracketing wires to guide surgery.
Several cases have appeared during the initial clinical trials with the PEM device in which breast biopsy on the basis of conventional radiological techniques missed a cancer focus (i.e., Figure 3 ) that was found soon thereafter with FDG PEM. These experiences suggest a role for FDG PEM in guiding breast biopsy, perhaps in cases where a strong a priori probability of cancer is present or where x-ray guided imaging was unable to detect a primary lesion when there is a strong clinical suspicion of cancer (e.g., when an axillary node is positive for cancer).
The PEM device appears sensitive in the detection of cancer recurrences (see Figure 5 ). Although one would imagine that the utility for these imaging studies would be limited to cases where the patient has undergone breast conserving therapy, initial data suggests that even mastectomy patients (i.e., after TRAM-flap reconstructive procedures) could benefit from surveillance with the PEM Flex device.
Initial feedback from the oncology community suggests a strong role for the PEM Flex device in objectively defined high-risk populations (28), where the utility of competitive techniques (e.g., MRI) may be limited by specificity. The biochemical specificity of PET suggests a strong role in drug development, particularly as applied to development of preventive agents. Currently, the cost and time involved in testing a preventive agent is prohibitive. If, however, the FDG PEM scan could reliably describe the regression of precancerous states (e.g., atypical ductal hyperplasia) to normalcy, one could imagine the use of the FDG PEM scan as a surrogate for testing preventive agents. As shown in pilot clinical trials, FDG PEM can detect regions of atypia and is likely to be able to monitor the response of these regions to interventions (21).
The changing nature of axillary sampling techniques may present new opportunities to FDG PEM. Initial enthusiasm for sentinel node procedures has been dampened by experience with associated morbidity and the long preparation times required for successful sentinel node localiza- tions. If the FDG PEM of the axilla demonstrated definite axillary involvement (as in Figure 6 ), some surgeons would rather perform an axillary dissection rather than proceed with sentinel node procedures.
The high sensitivity of FDG PEM to small deposits of cancer could potentially enable new classes of minimally invasive therapy. Without accurate road maps of tumor deposits, it will not be possible for minimally invasive therapy to succeed in removing cancers in their entirety. Since FDG PEM appears to have higher sensitivity for detecting in situ cells than other modalities, there would seem to be a strong role for this modality in guiding minimally invasive therapy. The ability to scan the breast immediately after therapy, to scan excised specimens immediately after removal, and to accomplish imaging of focal regions rapidly and with high diagnostic confidence would also confer strong advantages. Although the current production version of the PEM Flex device is not configured for use in the operating room, it is easy to envision a future version that would be ready for the operating room.
The collection of large population data with quantitative biochemical information represents an exceptional opportunity for basic and translational research. Translational research could include radiation treatment planning, as well as application of biochemically-based thresholding techniques for computer-assisted detection that could potentially complement existing feature-based systems employed in x-ray mammography.
Conclusions
Dedicated PET breast devices bring biochemical spatial resolution that appears capable of reliably imaging the earliest forms of breast cancer (e.g., DCIS). This capability is realized through improved spatial resolution and count collec-tion efficiency. Correlation with other modalities and avoidance of motion-unsharpness is achieved through implementation of mild compression (< 8 cm).
Initial clinical trials suggest that these devices have high diagnostic accuracy. On the basis of high sensitivity to intraductal spread of cancer, it is very likely that FDG PEM will have a major role to play in guiding breast biopsy, surgical planning, monitoring breast cancer recurrence, and surveillance of high-risk populations. Additional clinical trials are underway to explore applications to other arenas of breast health, including cancer prevention and minimally invasive therapy. At this time, it is premature to consider the use of the PEM scanner to obviate a clinically indicated biopsy procedure, or for screening purposes. In the future, if clinical trials continue to show high negative predictive value, future users may elect to undergo a FDG PEM scan in lieu of biopsy.
